ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Bausch + Lomb To Acquire ISTA In Cash Deal

DOW JONES NEWSWIRES Bausch + Lomb Monday agreed to acquire ISTA Pharmaceuticals Inc. (ISTA), swooping in with a higher offer for the eye-care company deal less than two months after a rival suitor withdrew its bid. ISTA shares jumped 7.8% to $9.03 after hours, slightly below Bausch + Lomb's $9.10 per-share offer price, which offers more than $380 million for Ista's outstanding shares. That values the company at a roughly 134% premium over its close Dec. 15, the day before ISTA confirmed its was weighing its strategic options. The latest offer comes after Valeant Pharmaceuticals International Inc. (VRX, VRX.T) withdrew a sweetened bid for the eye-care company. Valeant in January raised its offer for ISTA to $7.50 a share, with a target of $8.50 subject to due diligence. ISTA at the time said it would continue to review Valeant's offer, valued at up to $353 million, but said it would remain in talks with a number of parties that expressed interest in a strategic transaction. Basch + Lomb's deal, expected to close in the second quarter, won unanimous approval from both companies' boards. Basch + Lomb said the deal benefits from the two companies' complementary development pipelines. The companies plan to continue operating independently until the deal closes. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909;

Stock News for Valeant Pharma (VRX)
03/31/201516:39:35Statement of Changes in Beneficial Ownership (4)
03/31/201513:40:51Vital Signs Show the Market for Health-Deals Is In the Pink
03/31/201501:12:08Defensive Sectors Lead Hesitant Market, But Traders Honor Long-Standing...
03/27/201516:10:12Current Report Filing (8-k)
03/27/201510:40:43Valeant closes equity offering
03/27/201510:09:00Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common...
03/27/201510:09:00Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common...
03/27/201507:36:37Current Report Filing (8-k)
03/26/201514:11:57Why Synergy Pharmaceuticals, Inc. Is Surging Higher Today.
03/25/201519:56:37Lean Recipe Fuels Food Deals--Update
03/25/201511:57:13Statement of Beneficial Ownership (sc 13d)
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/22/201519:57:32Proceedings / Highlights From The Law Blog
03/18/201515:54:47Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
03/18/201506:04:06Current Report Filing (8-k)
03/17/201519:03:08Valeant prices equity offering
03/17/201509:00:00Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common...
03/17/201509:00:00Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common...
03/16/201519:47:24Valeant Raises Offer To $173/Share In New Deal for Salix--6th...
03/16/201519:36:19Valeant Raises Offer To $173/Share In New Deal for Salix--6th...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations